Tag: Gensight
Gensight Biologics: visibility until mid-February 2024 – 12/27/2023 at 09:43
(AOF) – Gensight Biologics announces that its cash flow horizon has been extended from mid-January to mid-February 2024. The biotech specializing in innovative gene therapies for retinal neurodegenerative diseases and…
GenSight: appointment of a new general director – 12/22/2023 at 12:37
(CercleFinance.com) – GenSight Biologics shares rose on Friday morning after the struggling biopharmaceutical company announced the appointment of Laurence Rodriguez, a former Sanofi Genzyme executive, to the position of CEO.…
GenSight Biologics: Laurence Rodriguez (ex-Sanofi) appointed CEO
(AOF) – GenSight Biologics announced the appointment of Laurence Rodriguez as Chief Executive Officer. The biotech specialist in gene therapies for retinal neurodegenerative diseases and central nervous system disorders specifies…
GenSight: Sofinnova Partners on the 20% stake
By Jean-Noël Legalland Published on 11/24/2023 at 2:25 p.m. Photo credit © Euronext (Boursier.com) — By letter received…
GenSight Biologics: a cash horizon extended until mid-December 2023
By Alexandra Saintpierre Published on 11/15/2023 at 6:14 p.m. Photo credit © Banque de France (Boursier.com) — The…
GenSight Biologics: the success of Lumevoq extends its horizon to mid-December 2023 – 11/15/2023 at 6:19 p.m.
(AOF) – GenSight Biologics announces that an independent laboratory confirms the viral titer of the second batch of Drug Substance (DS) for Lumevoq produced according to Good Manufacturing Practice (GMP)…
GenSight Biologics: the success of Lumevoq extends its horizon to mid-December 2023
(AOF) – GenSight Biologics announces that an independent laboratory confirms the viral titer of the second batch of Drug Substance (DS) for Lumevoq produced according to Good Manufacturing Practice (GMP)…
GenSight: the market welcomes the progress on Lumevoq
(CercleFinance.com) – GenSight Biologics jumped more than 30% on Wednesday morning on the Paris Stock Exchange after an update on its discussions with the European Medicines Agency (EMA) concerning its…
GenSight Biologics up sharply after production of 1st batch of GMP-compliant Lumevoq – 09/18/2023 at 11:06
(AOF) – GenSight Biologics (+60.78% to 0.66 euros) sees its stock skyrocket in high volumes after announcing that its production partner in the United States has successfully produced a batch…
GenSight: the title soars after an update on production – 09/18/2023 at 11:18
(CercleFinance.com) – GenSight Biologics soars on the Paris Stock Exchange on Monday morning after announcing that it had successfully produced a batch of its gene therapy intended for blind patients.…
Gensight biologics: The stock soars after an update on production
Read also (CercleFinance.com) – GenSight Biologics soars on the Paris Stock Exchange on Monday morning after announcing that it had successfully produced a batch of its gene therapy intended for…
GenSight Biologics: 1 million euros in cash, visibility until December – 09/15/2023 at 6:20 p.m.
(AOF) – GenSight Biologics sees its cash flow horizon extended until October 2023 thanks to the 1st tranche of financing of 10 million euros in August, and until December 2023…